Ayrshire Capital Management LLC Raises Position in Danaher Corporation $DHR

by · The Cerbat Gem

Ayrshire Capital Management LLC raised its position in shares of Danaher Corporation (NYSE:DHR – Free Report) by 3.0% during the 2nd quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 34,039 shares of the conglomerate’s stock after acquiring an additional 982 shares during the quarter. Danaher makes up approximately 3.2% of Ayrshire Capital Management LLC’s holdings, making the stock its 15th largest position. Ayrshire Capital Management LLC’s holdings in Danaher were worth $6,724,000 at the end of the most recent reporting period.

Other institutional investors have also recently made changes to their positions in the company. Focus Financial Network Inc. lifted its stake in shares of Danaher by 8.4% in the 2nd quarter. Focus Financial Network Inc. now owns 8,208 shares of the conglomerate’s stock valued at $1,621,000 after purchasing an additional 639 shares during the period. Sovran Advisors LLC lifted its position in Danaher by 1.6% during the second quarter. Sovran Advisors LLC now owns 4,759 shares of the conglomerate’s stock valued at $955,000 after buying an additional 76 shares during the period. Sivia Capital Partners LLC boosted its holdings in shares of Danaher by 6.3% during the 2nd quarter. Sivia Capital Partners LLC now owns 2,009 shares of the conglomerate’s stock valued at $397,000 after buying an additional 119 shares in the last quarter. Fjell Capital LLC grew its position in shares of Danaher by 2.7% in the 2nd quarter. Fjell Capital LLC now owns 2,451 shares of the conglomerate’s stock worth $484,000 after buying an additional 65 shares during the period. Finally, Bruce G. Allen Investments LLC increased its stake in shares of Danaher by 13.1% in the 2nd quarter. Bruce G. Allen Investments LLC now owns 467 shares of the conglomerate’s stock worth $92,000 after acquiring an additional 54 shares in the last quarter. Institutional investors own 79.05% of the company’s stock.

Danaher Stock Up 1.1%

DHR opened at $192.54 on Thursday. The company has a current ratio of 1.62, a quick ratio of 1.22 and a debt-to-equity ratio of 0.32. The company has a market capitalization of $137.87 billion, a PE ratio of 40.97, a PEG ratio of 2.66 and a beta of 0.75. Danaher Corporation has a 1-year low of $171.00 and a 1-year high of $279.90. The firm’s 50 day simple moving average is $200.61 and its two-hundred day simple moving average is $198.55.

Danaher (NYSE:DHR – Get Free Report) last announced its quarterly earnings data on Tuesday, July 22nd. The conglomerate reported $1.80 EPS for the quarter, beating the consensus estimate of $1.64 by $0.16. Danaher had a return on equity of 10.70% and a net margin of 14.21%.The business had revenue of $5.94 billion for the quarter, compared to the consensus estimate of $5.83 billion. During the same period in the previous year, the business earned $1.72 earnings per share. The business’s revenue was up 3.4% on a year-over-year basis. Danaher has set its FY 2025 guidance at 7.700-7.800 EPS. As a group, equities analysts forecast that Danaher Corporation will post 7.63 EPS for the current year.

Danaher Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Friday, October 31st. Stockholders of record on Friday, September 26th will be paid a dividend of $0.32 per share. This represents a $1.28 dividend on an annualized basis and a dividend yield of 0.7%. The ex-dividend date of this dividend is Friday, September 26th. Danaher’s payout ratio is currently 27.23%.

Analyst Ratings Changes

Several research firms recently commented on DHR. Scotiabank raised shares of Danaher from a “sector perform” rating to a “sector outperform” rating and set a $275.00 price objective on the stock in a research note on Friday, July 11th. Royal Bank Of Canada set a $241.00 price target on Danaher in a research report on Tuesday, September 2nd. Guggenheim restated a “buy” rating and issued a $250.00 price target on shares of Danaher in a research note on Wednesday, July 23rd. Wells Fargo & Company lowered their price objective on Danaher from $210.00 to $205.00 and set an “equal weight” rating for the company in a research note on Wednesday, July 23rd. Finally, UBS Group cut their target price on Danaher from $240.00 to $225.00 and set a “buy” rating on the stock in a research note on Wednesday, July 23rd. Seventeen research analysts have rated the stock with a Buy rating and three have issued a Hold rating to the company’s stock. According to data from MarketBeat, Danaher presently has an average rating of “Moderate Buy” and an average price target of $246.35.

Get Our Latest Stock Report on Danaher

Insider Buying and Selling

In other Danaher news, Director Teri List sold 2,778 shares of the business’s stock in a transaction dated Friday, August 22nd. The shares were sold at an average price of $211.06, for a total value of $586,324.68. Following the completion of the sale, the director directly owned 20,751 shares of the company’s stock, valued at $4,379,706.06. The trade was a 11.81% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. 11.10% of the stock is owned by corporate insiders.

About Danaher

(Free Report)

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.

Read More